Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioDlink International Co's quarterly market cap
increased
from Dec. 2024 (HK$1,298.1 Mil) to Jun. 2025 (HK$1,421.4 Mil) and
increased
from Jun. 2025 (HK$1,421.4 Mil) to Dec. 2025 (HK$1,813.0 Mil).
BioDlink International Co's annual market cap
declined
from Dec. 2023 (HK$1,428.6 Mil) to Dec. 2024 (HK$1,298.1 Mil) but then
increased
from Dec. 2024 (HK$1,298.1 Mil) to Dec. 2025 (HK$1,813.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioDlink International Co's Enterprise Value for Today is HK$2,980.5 Mil.
BioDlink International Co (HKSE:01875) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioDlink International Co Market Cap Related Terms
BioDlink International Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01875 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, BioDlink International Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioDlink International Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioDlink International Co's Market Cap distribution charts can be found below:
* The bar in red indicates where BioDlink International Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioDlink International Co (HKSE:01875) has a Market Cap of HK$2,915.3 Mil as of Aug. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioDlink International Co and its competitors. According to the industry distribution chart, BioDlink International Co ranks #481 out of 1422 companies in the Biotechnology industry, placing it in the top 33.8%.
Is BioDlink International Co's Market Cap too high?
BioDlink International Co's current Market Cap is HK$2,915.3 Mil. Based on the distribution chart, BioDlink International Co ranks #481 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioDlink International Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioDlink International Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioDlink International Co ranks #481 out of 1422 companies for Market Cap. This puts BioDlink International Co in the upper half of its industry. The industry median Market Cap is 122.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.48, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioDlink International Co and its competitors. For the Biotechnology industry, the median Market Cap is 122.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioDlink International Co's current Market Cap is HK$2,915.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioDlink International Co stock overvalued right now?
Based on GuruFocus' analysis, BioDlink International Co (HKSE:01875) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.47, compared to a current price of HK$4.02 — trading 173.5% above its estimated fair value. The current Market Cap is HK$2,915.3 Mil. BioDlink International Co's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioDlink International Co (HKSE:01875), the current Market Cap is HK$2,915.3 Mil as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioDlink International Co (HKSE:01875) Overvalued in 2026?
Based on GuruFocus' analysis, BioDlink International Co stock appears to be overvalued.
The current stock price of HK$4.02 is trading 173.5% above its estimated GF Value™ of HK$1.47.
GuruFocus considers BioDlink International Co to be Significantly Overvalued.
Key valuation signals for HKSE:01875:
Market Cap: HK$2,915.3 Mil
GF Value™: HK$1.47 vs. price of HK$4.02 (173.5% above fair value)
No single metric tells the full story. See the HKSE:01875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.
62GF Score
Get the complete analysis for HKSE:01875
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01875 has been successfully added to your 
